The stock market is trading at record highs once again, but not all stocks have participated in the big rally off the April lows, and those are the stocks I am constantly looking ...

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.

Merck & Co., Inc. (NYSE:MRK) is a leading pharmaceutical company, best known for its strong presence in oncology, ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A startling new vision of vaccination in America is becoming clearer — one likely to involve fresh scrutiny of established science and practices, and limits on vaccines that have been studied for ...

MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

In the latest trading session, Merck (MRK) closed at $78.83, marking a -1.05% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Meanwhile, the Dow gained 0.94%, and ...